2026 Market Trends Shaping Self-Funded Employers

For self-funded employers, 2026 brings rising complexity: elevated healthcare utilization, increasing specialty drug costs, more high-cost claims, and tighter stop-loss underwriting. Because these employers fund claims directly, these pressures can affect their plans faster and more visibly than in the fully insured market.

The Stop-loss Market Continues to Tighten

In 2026, rising claim severity and more large claims are reshaping the stop-loss market. Cancer treatment, specialty drugs, complex surgeries, and chronic illness are key drivers, prompting tighter underwriting, especially for plans with ongoing high-cost claims or significant specialty pharmacy exposure. At renewal, employers may notice:

• Increase underwriting scrutiny – Carriers increasingly request individual-level data on treatments, upcoming procedures, and specialty drug use, not just aggregate claims history, to identify participants at risk for catastrophic claims.
• Higher specific deductibles – Standard attachment points are rising across the board, not just for lasered individuals, as carriers anticipate more frequent large claims.
• More restrictive laser provisions – A laser assigns one high-risk individual a specific deductible, often two to three times the standard attachment point, shifting more risk to the employer.
• Closer review of specialty drug exposure – Carriers are scrutinizing formularies, not just total pharmacy spend. Some contracts now exclude pharmacy exposure or apply lasers to specific drug categories.

Provider Costs Continue to Climb

Hospitals and health systems face financial pressure, with labor accounting for roughly 60% of expenses, according to the American Hospital Association. Staff shortages, wage growth, and provider consolidation are driving costs higher, while mergers can increase reimbursement rates. Self-funded plans feel these increases immediately, making network design and reimbursement strategy essential for managing spend.

Specialty Pharmacy Remains a Key Cost Driver

Specialty drugs accounted for 53% of U.S. prescription spending in 2025, up 15.2% year over year. GLP-1 medications made up 11.4% of annual claims in 2026, up from 6.9% in 2023, while cancer, rare-disease, cell, and gene therapies continue to drive costs, often with six- or seven-figure price tags. Employers are responding by reviewing pharmacy benefit manager contracts, specialty-drug programs, formularies, and biosimilar options. For self-funded plans, these expenses affect spending immediately.

Utilization and Chronic Conditions

Healthcare spending is driven by utilization as well as price. Behavioral health needs and chronic conditions such as diabetes, cardiovascular disease, and obesity continue to drive claims, while an aging workforce adds demand. For self-funded plans, rising utilization appears directly in claims, making ongoing monitoring, condition management, and early intervention essential to long-term cost control.

Conclusion

Self-funded plans give employers flexibility to manage healthcare spending, but tighter stop-loss underwriting, specialty pharmacy costs, and rising utilization remain challenges. GLP-1s, cell and gene therapies, chronic disease, and sustained healthcare demand will remain key priorities heading into 2027. Download the bulletin for more details.